Pharmacological characterisation of MDI-222, a novel AMPA receptor positive allosteric modulator with an improved safety profile

Ward, Simon E. ORCID: https://orcid.org/0000-0002-8745-8377, Harries, Mark H., Aldegheri, Laura, Bradford, Andrea M., Ballini, Elisa, Dawson, Lee, Lacroix, Laurent, Pardoe, Joanne, Starr, Kathryn, Weil, Annette, Waters, Kerry, Atack, John R. ORCID: https://orcid.org/0000-0002-3410-791X and Woolley, Marie 2020. Pharmacological characterisation of MDI-222, a novel AMPA receptor positive allosteric modulator with an improved safety profile. Journal of Psychopharmacology 34 (1) , pp. 93-102. 10.1177/0269881119872198

Preview

PDF - Accepted Post-Print Version Download (451kB) | Preview

Abstract

There is considerable interest in positive allosteric modulators (PAMs) of the α-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate (AMPA) subtype of ionotropic glutamate receptors as therapeutic agents for a range of cognitive and mood disorders. However, the challenge is to increase AMPA receptor (AMPAR) function sufficient to enhance cognitive function but not to the extent that there are mechanism-related pro-convulsant or convulsant side effects. In this present study, we report the preclinical pharmacology data for MDI-222, an AMPAR PAM which enhances cognition but has a much reduced side-effect (i.e. convulsant) liability relative to other molecules of this mechanism.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine Biosciences
Publisher:	SAGE
ISSN:	0269-8811
Date of First Compliant Deposit:	2 January 2020
Date of Acceptance:	28 July 2019
Last Modified:	29 Nov 2024 22:15
URI:	https://orca.cardiff.ac.uk/id/eprint/128151

Citation Data

Cited 3 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item